A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 3, 2004, Pages 669-677

  Pascual, Julio ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Clinical efficacy; Rizatriptan; Tolerability; Triptans

Indexed keywords

ADRENERGIC RECEPTOR; ALMOTRIPTAN; BENZODIAZEPINE RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; DOPAMINE RECEPTOR; ELETRIPTAN; ERGOTAMINE; HISTAMINE RECEPTOR; MONOAMINE OXIDASE INHIBITOR; MUSCARINIC RECEPTOR; NARATRIPTAN; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PLACEBO; PROPRANOLOL; RECEPTOR SUBTYPE; RIZATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D AGONIST; SEROTONIN 1D RECEPTOR; SEROTONIN RECEPTOR; SUMATRIPTAN; ZOLMITRIPTAN;

ASTHENIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FATIGUE; HUMAN; LONG TERM CARE; META ANALYSIS; MIGRAINE; NAUSEA; OPEN STUDY; PATIENT SATISFACTION; RECURRENT DISEASE; REVIEW; SOMNOLENCE; TABLET DISINTEGRATION; TREATMENT PLANNING;

ACUTE DISEASE; ADMINISTRATION, ORAL; CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; MIGRAINE DISORDERS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; TRIAZOLES; TRYPTAMINES;

EID: 1542609883     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.3.669     Document Type: Review

References (44)

1. LIPTON RB, SILBERSTEIN SD, STEWART WF: An update on the epidemiology of migraine. Headache (1994) 34:319-328.
2. HEADACHE CLASSIFICATION SUBCOMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY. The International Classification of Headache Disorders (2nd edn). Cephalalgia (2004) 24(Suppl. 1):1-160.
3. GOADSBY PJ, LIPTON RB, FERRARI MD: Migraine - current understanding and treatment. N. Engl. J. Med. (2002) 346:257-270.
4. TFELT-HANSEN P, SAXENA PR, DAHLOF C et al.: Ergotamine in the acute treatment of migraine - a review and European consensus. Brain (2000) 123:9-18.
5. 1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet (2001) 358:1668-1675.
6. 1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia (2002) 22:633-658.
7. 1D receptor agonist for the treatment of migraine. Expert Opin. Investig. Drugs. (1999) 8:671-685.
8. TFELT-HANSEN P, DE VRIES P, SAXENA PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs (2000) 60:1259-1287.
9. DOOLEY M, FAULDS D: Rizatriptan. A review of its efficacy in the management of migraine. Drugs (1999) 58:699-723.
10. LONGMORE J, RAZZAQUE Z, SHAW D et al.: Comparison of the vasoconstrictor efficts of rizatriptan and sumatriptan in human isolated cranial arteries: Immunohistological demonstration of the involvement of 5-HT1B-receptors. Br. J. Clin. Pharmacol. (1998) 46:577-582.
11. 1D receptor agonists and human coronary artery reactivity in vitro: Crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br. J. Clin. Pharmacol. (1996) 42:431-441.
12. WILLIAMSON DJ, HILL RG, SHEPHEARD SL, HARGREAVES RJ: The anti-migraine 5-HT (1B71D) agonist rizatriptan inhibits neurogenic dural vasodilation in anesthetized guinea-pigs. Br. J. Pharmacol. (2001) 133:1029-1034.
13. WILLIAMSON DJ, SHEPHEARD SL, HILL RG, HARGREAVES RJ: The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur. J. Pharmacol. (1997) 328:37-40.
14. CUMBERBATCH MJ, HILL RG, SHEPHEARD SL, HARGREAVES R: Rizatriptan has central antinociceptive effects against durally evoked responses. Eur. J. Pharmacol. (1997) 328:49-54.
15. DAHLOF C, RAPOPORT AM, SHEFTELL FD, LINES C: Rizatriptan in the treatment of migraine. J. Drug. Ther. (1999) 21:1823-1836.
16. WELLINGTON K, PLOSKER GL: Rizatriptan. An update of its use in the management of migraine. Drugs (2002) 62:1539-1754.
17. 1B/1D agonist: Differential effects of propranolol, nadolol and metoprolol. Br. J. Clin. Pharmacol. (2001) 52:69-76.
18. TFELT-HANSEN P, SEIDELIN K, STEPANAVAGE M, LINES C: The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: A double-blind, placebo-controlled, crossover study in normal subjects. Br. J. Clin. Pharmacol. (2002) 54:38-44.
19. SHADLE CR, LIU G, GOLDBERG MR: A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers. J. Clin. Pharmacol. (2000) 40:309-315.
20. GOLBERG MR, LOWRY RC, MUSSON DG et al.: Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. J. Clin. Pharmacol. (1999) 39:192-199.
21. TEALL J, TUCHMAN M, CUTLER N et al., ON BEHALF OF THE RIZATRIPTAN 022 STUDY GROUP: Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence: A placebo-controlled, outpatient study. Headache (1998) 38:281-287.
22. GOLDSTEIN J, RYAN R, JIANG K et al., ON BEHALF OF THE RIZATRIPTAN PROTOCOL 046 STUDY GROUP: Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache (1998) 38:737-747.
23. GIJSMAN H, KRAMER MS, SARGENT J et al.: Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia (1997) 17:647-651.
24. TFELT-HANSEN P, TEALL J, RODRIGUEZ F et al., ON BEHALF OF THE RIZATRIPTAN 030 STUDY GROUP: Oral riAatriptan versus oral sumatriptan: a direct comparison study in the acute treatment of migraine. Headache (1998) 39:748-755.
25. VISSER WH, TERWINDT GM, REINES SA, JIANG K, LINES CR, FERRARI MD: Rizatriptan versus sumatriptan in the acute treatment of migraine. Arch. Neurol. (1996) 53:1132-1137.
26. LINES C, VISSER H, VANDORMAEL K, REINES SA: Rizatriptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine. Headache (1997) 37:319-320.
27. KRAMER MS, MATZURA-WOLFE D, POLIS A et al., ON BEHALF OF THE RIZATRIPTAN MULTIPLE ATTACK STUDY GROUP: A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology (1998) 51:773-781.
28. LIPTON RB, PASCUAL J, GOADSBY PJ et al.: Effect of rizatriptan and other triptans on the nausea symptom of migraine: A post hoc analysis. Headache (2001) 41:754-763.
29. BUSSONE G, D'AMICO D, MCCARROLL KA, GERTH W, LINES CR: Restoring migraine sufferers' ability to function normally: A comparison of rizatriptan and other triptans in randomized trials. Eur. Neurol. (2002) 48:172-177.
30. ADELMAN JU, LIPTON RB, FERRARI MD et al.: Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology (2001) 57:1377-1383.
31. BOMHOF M, PAZ J, LEGG N, ALLEN C, VANDORMAEL K, PATEL K, AND THE RIZATRIPTAN-NARATRIPTAN STUDY GROUP: Comparison of rizatriptan 10 mg versus naratriptan 2,5 mg in migraine. Eur. Neurol. (1999) 42:173-179.
32. PASCUAL J, VEGA P, DIENER HC, ALLEN C, VRIJENS F, PATEL K, ON BEHALF OF THE RIZATRIPTAN-ZOLMITRIPTAN STUDY GROUP: Comparison of rizatriptan 10 mg versus zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia (2000) 20:455-461.
33. BLOCK GA, GOLDSTEIN J, POLIS A, REINES SA, SMITH ME, ON BEHALF OF THE RIZATRIPTAN MULTICENTER GROUP: Efficacy and safety of rizatriptan versus standard care during long-term treatment of migraine. Headache (1998) 38:764-771.
34. AHRENS SP, FARMAER MV, WILLIAMS DL et al.: Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia (1999) 19:525-530.
35. PASCUAL J, BUSSONE G, HERNANDEZ JF, ALLEN C, VRIJENS F, PATEL K, ON BEHALF OF THE RIZATRIPTAN-SUMATRIPTAN PREFERENCE STUDY GROUP: Comparison of preference for rizatriptan 10 mg wafer versus sumatriptan 50 mg tablet in migraine. Eur. Neurol. (2001) 45:275-283.
36. LODER E, BRANDES JL, SILBERSTEIN SD et al., ON BEHALF OF THE RIZATRIPTAN PROTOCOL 060 STUDY GROUP: Preference comparison of rizatriptan ODT 10 mg and sumatriptan 50 mg tablet in migraine. Headache (2001) 41:745-753.
37. ADELMAN JU, MANNIX LK, VON SEGGERN RL: Rizatriptan tablet versus wafer: Patient preference. Headache (2000) 40:371-372.
38. GERTH WC, MACCAROLL KA, SANTANELLO NC: Patient satisfaction with rizatriptan versus other triptans: Direct head-to-head comparisons. Int. J. Clin. Pract. (2001) 55:552-556.
39. CHRISTIE S, GOBEL H, MATEOS V et al.: Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur. Neurol. (2003) 49:20-29.
40. BELSEY J: Reconciling effectiveness and tolerability in oral triptan therapy: A quantitative approach to decision making in migraine management. J. Clin. Res. (2001) 4:105-125.
41. LIPTON RB, STEWART WF: Acute migraine therapy. Do doctors understand what patients with migraine want from therapy? Headache (1999) 35:601-606.
42. DAHLOF CGH, LIPTON RB, MACCARROLL KA, KRAMER MS, LINES CR, FERRARI MD: Within-patient consistency of response of rizatriptan for treating migraine. Neurology (2000) 55:1511-1516.
43. PASCUAL J, FITE B, LOPEZ GIL A: Comparison of triptan tablet consumption per attack: A prospective study of migraineurs in Spain. Headache (2002) 42:93-98.
44. LEIRA R, DUALDE E, DEL BARRIO H, MACHUCA M, LOPEZ-GIL A, SPANISH GROUP FOR THE STUDY OF TRIPTAN CONSUMPTION IN COMMUNITY PHARMACIES: Almotriptan versus rizatriptan in patients with migraine in Spain. Headache (2003) 43:734-741.